{'fraction_non_alphanumeric': 0.025495750708215296, 'fraction_numerical': 0.02927289896128423, 'mean_word_length': 4.988700564971752, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influence of haemochromatosis gene mutations on treatment outcomes in patients with hepatitis C

Interferon alpha-2a (3 million units three times weekly for 6 or 12 months) was given to 98 subjects with chronic hepatitis C. At the end of treatment, 58 subjects were classified as non-responders (positive hepatitis C virus (HCV) polymerase chain reaction (PCR) at end of treatment) and 40 were responders (negative HCV PCR at end of treatment). Thirtyseven of the 40 responders had post-treatment follow up and 17 of 37 were sustained responders (negative HCV PCR 6 months post-treatment). Blood samples were analysed for the C282Y and the H63D mutations in the HFE gene by PCR, restriction enzyme digestion and electrophoresis. Liver iron content was visually quantified using Perls’ iron stain and the hepatic inflammatory grade and stage of fibrosis were recorded. The HFE gene mutations and genotype frequencies of the 98 subjects in the study group were almost identical to those of 1064 patients randomly selected from the general population (Table 1).3